Johnson & Johnson to buy Biopsys

Article

Healthcare giant Johnson & Johnson of New Brunswick, NJ, has agreed to buy minimally invasive surgical developer Biopsys Medical of Irvine, CA, in a stock swap valued at $310 million. Biopsys manufactures Mammotome, a biopsy gun that uses a vacuum

Healthcare giant Johnson & Johnson of New Brunswick, NJ, has agreed to buy minimally invasive surgical developer Biopsys Medical of Irvine, CA, in a stock swap valued at $310 million. Biopsys manufactures Mammotome, a biopsy gun that uses a vacuum method for removing breast tissue. The merger is subject to approval by Biopsys shareholders and regulatory authorities.

The amount of Johnson & Johnson stock that will be issued for each Biopsys share will be based on a formula in which $27.55 will be divided by the average closing price per J&J share for each of the 20 trading days preceding the last full trading day prior to a meeting of Biopsys shareholders to approve the merger. Biopsys shares closed at $26.69 the day the merger was announced.

Recent Videos
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
What New Research Reveals About the Impact of AI and DBT Screening: An Interview with Manisha Bahl, MD
Can AI Assessment of Longitudinal MRI Scans Improve Prediction for Pediatric Glioma Recurrence?
A Closer Look at MRI-Guided Adaptive Radiotherapy for Monitoring and Treating Glioblastomas
Incorporating CT Colonography into Radiology Practice
What New Research Reveals About Computed Tomography and Radiation-Induced Cancer Risk
What New Interventional Radiology Research Reveals About Treatment for Breast Cancer Liver Metastases
New Mammography Studies Assess Image-Based AI Risk Models and Breast Arterial Calcification Detection
Can Deep Learning Provide a CT-Less Alternative for Attenuation Compensation with SPECT MPI?
Related Content
© 2025 MJH Life Sciences

All rights reserved.